GH administration and neutralization of TNFα reduce mucosal inflammation in experimental colitis (14); by altering tolerization mechanisms such as the cytokine environment, macrophage polarization, activation of the suppressor T cell population, and Th17 cell plasticity, GH also reduces type I diabetes development (15). Here, GH1 is linked to colitis.